Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Corneo

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Haematologica|December 10, 1999
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical studyR Bassan, E Pogliani, T Lerede, et al.
Science (New York, N.Y.)|September 25, 2001
Roots of clinical resistance to STI-571 cancer therapyA Hochhaus, S Kreil, A Corbin, et al.
Journal of the National Cancer Institute|October 19, 2000
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571C Gambacorti-Passerini, R Barni, P le Coutre, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groupsR Bassan, E Pogliani, P Casula, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Haematologica|December 10, 1999
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical studyR Bassan, E Pogliani, T Lerede, et al.
Science (New York, N.Y.)|September 25, 2001
Roots of clinical resistance to STI-571 cancer therapyA Hochhaus, S Kreil, A Corbin, et al.
Journal of the National Cancer Institute|October 19, 2000
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571C Gambacorti-Passerini, R Barni, P le Coutre, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groupsR Bassan, E Pogliani, P Casula, et al.
Pageof 8